Ranbaxy opens third centre in India
Ranbaxy Laboratories (RL) has opened its third drug discovery research centre in Gurgaon, India.
Ranbaxy Laboratories (RL) has opened its third drug discovery research centre in Gurgaon, India.
Commenting at the formal inauguration by the president of India, Dr. A.P.J. Abdul Kalam, Dr. Brian Tempest, ceo and md, said: 'we believe that r&d is one of our key competitive strengths and the addition of this facility further enhances our capabilities in the area of drug discovery and development systems.'
The centre is housed in a new building in the same campus as Ranbaxy's earlier research facilities. It will focus on new drug discovery and development (NDDR), analytical development, pharmacology, molecular technologies, infectious diseases, metabolism and pharmacokinetics. The other two facilities are used for the development of generics and novel drug delivery systems. The company also has another r&d building which houses its regulatory and administrative departments.
Ranbaxy's focus areas for research are infectious diseases, urology, respiratory/inflammatory and metabolic diseases. It presently has around eight to 10 NDDR programmes, including two NCEs (New Chemical Entities), in the clinical phase of development.